Lørenskog, Norway - Elevated concentrations of cardiac troponin I (cTnI) in patients with stable coronary artery disease (CAD) are associated with an increased risk of cardiovascular death or heart failure, as well as a significantly increased risk of nonfatal MI, according to the results of a new study . In this new analysis, increases in cTnI, detected using a highly sensitive assay, were associated with an 88% higher risk of cardiovascular death or heart failure and a 44% increased risk of nonfatal MI.
"The development of more sensitive assays has opened up a new perspective on the use of troponins," lead investigator Dr Torbjørn Omland (Akershus University Hospital, Lørenskog, Norway) told heartwire. "In patients with stable coronary artery disease, the large majority of these patients will have detectable circulating troponin levels, and these low concentrations do seem to be closely related to future risk, in particular the development of heart failure and death. It suggests that these high-sensitivity troponins can be used in a new setting outside the traditional acute coronary syndrome [ACS] patient. It provides complementary information to the traditional risk factors."
The new study, an analysis of the Prevention of Events with Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE) trial, is published online February 13, 2013 in the Journal of the American College of Cardiology.